Skip to main content
All lobbying filings

TODD STRATEGY GROUP

Lobbying for ASTRAZENECA PHARMACEUTICALS LP · ​Biopharmaceutical Company.

 Filing Registration amendment
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 14, 2025
Money reported
None
Registrations and no-activity reports carry no figure.
Client based in
Delaware

Official filing document

 Lobbyists on this filing 5
  • PAUL EDATTEL New on this filing
    Previously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
  • ERIC BERGREN New on this filing
    Previously held: Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
  • DANIEL M TODD New on this filing
    Previously held: Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid
  • KATHERINE FLEMING COTTON New on this filing
    Previously held: Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie
  • TED LEHMAN New on this filing
    Previously held: Chief of Staff, Senator Tillis; Senate Judiciary Committee-Counsel, then Chief Counsel for Nominations and Senior Counsel; Senate Judiciary Committee-Staff Assistant and Legislative Assistant

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Lobbying activity 2

340B Program. Home Infusion for Part B Products. Medicare Reimbursement for New Technologies. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection.

340B Program. Home Infusion for Part B Products. Medicare Reimbursement for New Technologies. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem